Väljaminev kiriAvalik
Farmakopöa töökava asjus
Ravimiamet · 24. oktoober 2025
- Viit
- REP-1/5620-2
- Registreeritud
- 24. oktoober 2025
- Dokumendi liik
- Väljaminev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2025
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Addition to the work programme P4: Cariprazine hydrochloride and
Cariprazine hydrochloride capsules
page 1 / 3
Q1-4 (4425)
NPA: (55286)
Type: (!/list-dropdown)
A10 - Estonia (EE)
Please inform if you are in favour of the addition of Cariprazine hydrochloride to the work
programme:
(55287)
Type: (L/list-radio)
In favour of the addition of Cariprazine hydrochloride to the work programme
A1
If opposed to this addition to the work programme, please state why. (55288)
Type: (T/text-long)
-
page 2 / 3
Please inform if you are in favour of the addition of Cariprazine hydrochloride capsules to the
work programme:
(55290)
Type: (L/list-radio)
In favour of the addition of Cariprazine hydrochloride capsules to the work programme
A1
If opposed to this addition to the work programme, please state why. (55289)
Type: (T/text-long)
-
Remarks: (55291)
Type: (T/text-long)
-
page 3 / 3